Our Focus on Immuno-Oncology

In the field of immuno-oncology, the STAM™ mouse is the most pathologically suitable model for developing new therapeutic drugs for liver cancer.

The utilization of STAM™ mouse enables non-clinical research for the development of liver cancer therapeutics targeting immune cells, tumor microenvironment, and genetic mutations.

READ MORE

NEWS RELEASE

Devonian Reports Positive Results in MASH Liver Study

In a great collaboration with Devonian Health Group Inc., we are happy to demonstrate preclinical proof of concept for Thykamine™ using our STAM (MASH-HCC model) mouse.   Thykamine™ treatment in STAM mice demonstrated improvements in NAS and fibrosis—key endpoints in clinical trials. Beyond atopic dermatitis and ulcerative colitis, Thykamine™ has also shown promising anti-inflammatory and…

READ MORE

EVENT

SMC will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology

We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology from May 9th (Thu) to 11th (Sat).   In the Exhibition section, we will introduce our drug efficacy evaluation study services using our original MASH (NASH)-hepatocarcinoma model, STAM™ mouse, as well as other…

READ MORE

New

Human Cell

“Role of hepatocellular senescence in the development of hepatocellular carcinoma and the potential for therapeutic manipulation” (Human Cell, DOI: 10.1007/s13577-025-01201-2, 2025)

READ MORE

STAM™ Model | MASH & Fibrosis & HCC

Our STAM™ model is a model that recapitulates the same disease progression as human MASH/HCC.

READ MORE

SERVICE

Search by topics

Our Patented original technologySTAM™ mouse

We are contributing to the world through providing cutting-edge non-clinical pharmacology studies with our unique patented technology, the STAM™ mouse. In order to develop a new drug, it is important to be able to accurately measure the effectiveness of the drug at the non-clinical trial stage. The STAM™ mouse, a model that more accurately reflects human pathology, plays a major role for this purpose.

LEARN MORE

COLUMN

2025.05.23

Visit SMC at the 61st Annual Meeting of the Japan Society of Hepatology

Today, we are excited to announce that we will be attending the “61st Annual Meeting of the Japanese Society of Hepatology” which will be held on June 5th, Thursday and June 6th, Friday, at New Otani Hotel (Tokyo). We will be happy to introduce our disease mouse models of inflammation and fibrosis in various organs,…

READ MORE

2025.05.16

Proposals to evaluate single test substance with multiple models

Today, we’d like to make suggestions on how to maximize the value of your preclinical data you have obtained with us. 2 strategic approaches to expand the potential of drug development We propose the following approaches for further expansion of your current drug development. Proposal 1: Indication expansion strategy: Expanding disease area In recent years,…

READ MORE

2025.05.09

Unlock the Full Potential of Your Compounds: A Proposal for Tailored Evaluation Solutions

In today’s increasingly competitive landscape of new drug development, where a more individualized approach is crucial, are you encountering challenges such as: – “Existing models and evaluation systems fall short of fully assessing the unique characteristics of our company’s compounds.” – “Commonly used models lack reproducibility, leading to wasted time and resources.” – “We want…

READ MORE

2025.05.02

Addressing Unmet Needs with Tailored Non-Clinical Solutions

Idiopathic Pulmonary Fibrosis (IPF) remains a high-priority therapeutic area, where current standard-of-care (SOC) treatments such as Nintedanib and Pirfenidone help slow disease progression, but do not halt it entirely. Despite treatment, mortality remains high, and there is limited improvement in quality of life and overall survival. The urgent need for safer and more effective therapies…

READ MORE

2025.04.25

Liraglutide Evaluation in the CDAHFD Model

We would like to share with you our latest data obtained using the CDAHFD (Choline-Deficient, High-Fat Diet) mouse model, which rapidly reproduces key features of MASH, including steatosis, inflammation, and fibrosis. In this study, we evaluated the GLP-1 receptor agonist Liraglutide, and observed a clear anti-fibrotic effect in this model.   Overview of the CDAHFD Model Induced by a…

READ MORE

2025.04.18

Obese MASH model

We will introduce the obese MASH model in this article.   Existing MASH (metabolic dysfunction-associated steatohepatitis) models have different characteristics, such as obese/non-obese type, presence/absence of dyslipidemia, and differences regarding the capability to progression to HCC. Since MASH is a complex disease with diverse ways of pathogenesis, it is important to evaluate your test substance in multiple…

READ MORE

VIEW MORE

MODEL LINEUP

Introducing disease mice models related to inflammation, fibrosis, metabolic disorder, cancer, and cancer immunity, including the STAM™ mouse, the world's first MASH model mouse developed in our company.

STAM™ Model | MASH & Fibrosis & HCC

DISEASE AREAMASH/NASH-HCCTHERAPEUTIC AREAS

LEARN MORE

Bleomycin-induced pulmonary fibrosis model

DISEASE AREAIPFTHERAPEUTIC AREAS

LEARN MORE

Porcine Pancreatic Elastase (PPE) model

COPDDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

CCl4-induced liver fibrosis model

CirrhosisDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

Bile duct ligation (BDL) model

DISEASE AREAPBCTHERAPEUTIC AREAS

LEARN MORE

TAA-induced acute liver failure model

ALFDISEASE AREATHERAPEUTIC AREAS

LEARN MORE

VIEW MORE

New stage

Our service and disease mouse models bridge the development of the next- Generation Cancer Therapies in the field of Immuno-oncology.

LEARN MORE

New stage

SMC Laboratories,Inc.

COMPANY

At SMC Laboratories, we support drug research with our cutting-edge non-clinical pharmacology studies to quickly deliver therapeutic drugs to patients suffering from diseases that cannot be treated with existing drugs.

LEARN MORE

PUBLICATION

We, SMC Laboratories, are highly regarded worldwide as a consulting – based CRO that designs tailored to the needs of pharmaceutical companies and research institutions.

NEWS

2025.05.16

Exhibition Announcement: SMC Laboratories to Exhibit at the 61st Annual Meeting of the Japan Society of Hepatology

SMC Laboratories, Inc. is pleased to announce our participation in the 61st Annual Meeting of the Japan Society of Hepatology, to be held on June 5–6, 2025, at Hotel New Otani, Tokyo.   We will once again be showcasing our preclinical models, including the STAM™ mouse for MASH and MASH-HCC, along with other inflammation- and…

READ MORE

2025.05.02

Hepatocellular Senescence Linked to Liver Cancer Development: Sirolimus Shows Preventive Potential in Preclinical Study

A new study published in Human Cell by researchers at the University of Nottingham highlights the role of hepatocellular senescence in the progression to hepatocellular carcinoma (HCC). The study further demonstrates that sirolimus, an mTOR inhibitor, can prevent HCC development by suppressing the secretion of senescence-associated secretory phenotype (SASP) factors.   The team analyzed liver…

READ MORE

2025.04.15

IL-18 Binding Protein Shows Promise in Suppressing Fibrosis in MASH: New Study Published in Cell Reports Medicine

A recent study published in Cell Reports Medicine (April 2025) reports that treatment with an IL-18 binding protein (IL-18BP) significantly suppresses the progression of fibrosis in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). The findings highlight IL-18BP as a potential new therapeutic strategy for managing MASH.   In this preclinical study, IL-18BP was administered…

READ MORE

2025.03.04

NEWS RELEASE

Devonian Reports Positive Results in MASH Liver Study

In a great collaboration with Devonian Health Group Inc., we are happy to demonstrate preclinical proof of concept for Thykamine™ using our STAM (MASH-HCC model) mouse.   Thykamine™ treatment in STAM mice demonstrated improvements in NAS and fibrosis—key endpoints in clinical trials. Beyond atopic dermatitis and ulcerative colitis, Thykamine™ has also shown promising anti-inflammatory and…

READ MORE

2025.02.28

New possibilities for MASH treatment: Confirmation of the effectiveness of 2-hydroxybenzylamine

A new study published in the Feb 2025 issue of Nutrients highlights the therapeutic promise of 2-hydroxybenzylamine (2-HOBA) in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The research demonstrates that 2-HOBA effectively scavenges reactive dicarbonyl compounds, leading to reduced hepatic inflammation and fibrosis, and improved liver function. In this study, MASH model mice were treated…

READ MORE

2025.02.28

NEWS RELEASE

CytoDyn Reports Significant Fibrosis Reversal in SMC Lab Studies

In a great collaboration with CytoDyn Inc., we are pleased to share promising preclinical results demonstrating the efficacy of leronlimab (a CCR5 antagonist) in liver disease models. Using our STAM (MASH-HCC) and CCl₄-induced liver fibrosis models, leronlimab monotherapy successfully reversed liver fibrosis—an area with significant unmet medical need.   These findings suggest that leronlimab’s anti-fibrotic…

READ MORE

VIEW MORE